Preparation and in vitro and in vivo characterization of cyclosporin A-loaded, PEGylated chitosan-modified, lipid-based nanoparticles

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 601-610

  Zhang, Ling ^a   Zhao, Zhi Liang ^b   Wei, Xiao Hong ^a   Liu, Jin Hua ^a  

^a HANGZHOU NORMAL UNIVERSITY   (China)

^b Tongde Hospital of Zhejiang Province   (China)

Author keywords

Bioavailability; Chitosan; Cyclosporin A; Long circulation; Nanoparticle; PEGylation; Pharmacokinetics

Indexed keywords

CHITOSAN; CYCLOSPORIN A; LIPID; NANOPARTICLE; SOLVENT; TAMOXIFEN;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CHEMICAL MODIFICATION; CHEMICAL REACTION; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG RELEASE; DRUG SYNTHESIS; EMULSION; ENCAPSULATION; EVAPORATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; LIGHT SCATTERING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PARTICLE SIZE; PHARMACOKINETICS; SINGLE DRUG DOSE; TRANSMISSION ELECTRON MICROSCOPY;

BIOAVAILABILITY; CHITOSAN; CYCLOSPORIN A; LONG CIRCULATION; NANOPARTICLE; PEGYLATION; PHARMACOKINETICS;

ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHITOSAN; CYCLOSPORINE; NANOPARTICLES; POLYETHYLENE GLYCOLS; RABBITS;

EID: 84873624680     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S39685     Document Type: Article

References (39)

1. Pillai AA, Levitsky J. Overview of immunosuppression in liver transplantation. World J Gastroenterol. 2009;15:4225-4233.
2. Chadban S. New-onset diabetes after transplantation-should it be a factor in choosing an immunosuppressant regimen for kidney transplant recipients? Nephrol Dial Transplant. 2008;23:1816-1818.
3. Przepiorka D, Devine SM, Fay JW, Uberti JP, Wingard JR. Practical considerations in the use of tacrolimus for allogeneic marrow transplantation. Bone Marrow Transplant. 1999;24:1053-1056.
4. Bobadilla NA, Gamba G. New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone. Am J Physiol Renal Physiol. 2007;293:F2-F9.
5. Wijdicks EF. Neurotoxicity of immunosuppressive drugs. Liver Transpl. 2001;7:937-942.
6. Ginsburg PM, Thuluvath PJ. Diarrhea in liver transplant recipients: etiology and management. Liver Transpl. 2005;11:881-890.
7. Tedesco D, Haragsim L. Cyclosporine: a review. J Transplant. 2012; 2012:230386.
8. Roby KA, Shaw LM. Effects of cyclosporine and its metabolites in the isolated perfused rat kidney. J Am Soc Nephrol. 1993;4:168-177.
9. Beauchesne PR, Chung NS, Wasan KM. Cyclosporine A: a review of current oral and intravenous delivery systems. Drug Dev Ind Pharm. 2007;33:211-220.
10. Italia JL, Bhardwaj V, Ravi Kumar MN. Disease, destination, dose and delivery aspects of ciclosporin: the state of the art. Drug Discov Today. 2006;11:846-854.
11. Andrysek T. Impact of physical properties of formulations on bioavailability of active substance: current and novel drugs with cyclosporine. Mol Immunol. 2003;39:1061-1065.
12. Onoue S, Sato H, Kawabata Y, Mizumoto T, Hashimoto N, Yamada S. In vitro and in vivo characterization on amorphous solid dispersion of cyclosporine A for inhalation therapy. J Control Release. 2009;138: 16-23.
13. Al-Meshal MA, Khidr SH, Bayomi MA, Al-Angary AA. Oral administration of liposomes containing cyclosporine: a pharmacokinetic study. Int J Pharm. 1998;168:163-168.
14. Italia JL, Bhatt DK, Bhardwaj V, Tikoo K, Ravi Kumar MNV. PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral®. J Control Release. 2007;119:197-206.
15. Müller RH, Runge SA, Ravelli V, Thünemann AF, Mehnert W, Souto EB. Cyclosporine-loaded solid lipid nanoparticles (SLN®): drug-lipid physicochemical interactions and characterization of drug incorporation. Eur J Pharm Biopharm. 2008;68:535-544.
16. Azzi J, Tang L, Moore R, et al. Polylactide-cyclosporin A nanoparticles for targeted immunosuppression. FASEB J. 2010;24:3927-3938.
17. Frusic-Zlotkin M, Soroka Y, Tivony R, et al. Penetration and biological effects of topically applied cyclosporin A nanoparticles in a human skin organ culture inflammatory model nanoparticles in a human skin organ culture inflammatory model. Exp Dermatol. 2012;21:938-943.
18. Vadiei K, Perez-Soler R, Lopez-Berestein G, Luke DR. Pharmacokinetic and pharmacodynamic evaluation of liposomal cyclosporine. Int J Pharm. 1989;57:125-131.
19. Woodle MC. Sterically stabilized liposome therapeutics. Adv Drug Deliv Rev. 1995;16:249-265.
20. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today. 2005;10:1451-1458.
21. Hooftman G, Herman S, Schacht E. Review: poly(ethylene glycol)s with reactive endgroups. II. Practical consideration for the preparation of protein-PEG conjugates. J Bioact Compat Polym. 1996;11:135-159.
22. Kataoka K, Kwon GS, Yokoyama M, Okano T, Sakurai Y. Block copolymer micelles as vehicles for drug delivery. J Control Release. 1993;24:119-132.
23. Bhattarai N, Ramay HR, Gunn J, Matsen FA, Zhang M. PEG-grafted chitosan as an injectable thermosensitive hydrogel for sustained protein release. J Control Release. 2005;103:609-624.
24. Kean T, Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv Rev. 2010;62:3-11.
25. Prego C, Torres M, Garci{dotless}a D, Alonso MJ. Transmucosal macromolecular drug delivery. J Control Release. 2005;101:151-162.
26. Guzman E, Cavallo JA, Chulia-Jordan R, et al. pH-induced changes in the fabrication of multilayers of poly(acrylic acid) and chitosan: fabrication, properties, and tests as a drug storage and delivery system. Langmuir. 2011;27:6836-6845.
27. Guzman E, Chulia-Jordan R, Ortega F, Rubio RG. Influence of the percentage of acetylation on the assembly of LbL multilayers of poly(acrylic acid) and chitosan. Phys Chem Chem Phys. 2011;13:18200-18207.
28. Wei XH, Liang WQ. The preparation and characterization of mPEGylated chitosan as a gene vector. Chinese J Modern Appl Pharm. 2003;20:383-385.
29. Chan P, Kurisawa M, Chung JE, Yang Y-Y. Synthesis and characterization of chitosan-g-poly (ethylene glycol)-folate as a non-viral carrier for tumor-targeted gene delivery. Biomaterials. 2007;28:540-549.
30. Jie L-Y, Cai L-L, Wang L-J, et al. Actively-targeted LTVSPWY peptide-modified magnetic nanoparticles for tumor imaging. Int J Nanomedicine. 2012;7:3981-3989.
31. Hu F-Q, Meng P, Dai Y-Q, et al. PEGylated chitosan-based polymer micelle as an intracellular delivery carrier for anti-tumor targeting therapy. Eur J Pharm Biopharm. 2008;70:749-757.
32. Wei X-H, Niu Y-P, Xu Y-Y, Du Y-Z, Hu F-Q, Yuan H. Salicylic acid-grafted chitosan oligosaccharide nanoparticle for paclitaxel delivery. J Bioact Compat Polym. 2010;25:319-335.
33. Chimalakonda AP, Shah RB, Mehvar R. High-performance liquid chromatographic analysis of cyclosporin A in rat blood and liver using a commercially available internal standard. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;772:107-114.
34. Woranuch S, Yoksan R. Eugeno l-loaded chitosan nanoparticles: I. Thermal stability improvement of eugenol through encapsulation. Carbohydr Polym. 2012.
35. Tripathy S, Das S, Chakraborty SP, Sahu SK, Pramanik P, Roy S. Synthesis, characterization of chitosan-tripolyphosphate conjugated chloroquine nanoparticle and its in vivo anti-malarial efficacy against rodent parasite: A dose and duration dependent approach. Int J Pharm. 2012;434:292-305.
36. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15:25-35.
37. Lee PI, Peppas NA. Prediction of polymer dissolution in swellable controlled-release systems. J Control Release. 1987;6:207-215.
38. Shen J, Deng YP, Jin XF, Ping QE, Su ZG, Li LJ. Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: improving in vivo ocular distribution. Int J Clin Pharm. 2010;402:248-253.
39. Gibaldi M, Perrier D. Pharmacokinetics. Revised and Expanded, 2nd ed. New York, NY: Marcel Dekker; 1982.